These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24839948)

  • 1. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
    Dutreix C; Lorenzo S; Wang Y
    Eur J Clin Pharmacol; 2014 Aug; 70(8):915-20. PubMed ID: 24839948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
    Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
    Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
    Tahara H; Watanabe M; Hasegawa M
    Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.
    Jiang X; Dutreix C; Jarugula V; Rebello S; Won CS; Sun H
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):19-26. PubMed ID: 27138546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Dispos; 2013 Aug; 41(8):1488-93. PubMed ID: 23674608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction.
    Mårde Arrhén Y; Nylén H; Lövgren-Sandblom A; Kanebratt KP; Wide K; Diczfalusy U
    Br J Clin Pharmacol; 2013 Jun; 75(6):1536-40. PubMed ID: 23116409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
    Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
    Rodrigues AD; Wood LS; Vourvahis M; Rowland A
    Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
    Zhu YT; Zhang YF; Jiang JF; Yang Y; Guo LX; Bao JJ; Zhong DF
    Invest New Drugs; 2021 Aug; 39(4):1011-1018. PubMed ID: 33506323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
    Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
    Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
    Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
    Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
    Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity.
    Hukkanen J; Puurunen J; Hyötyläinen T; Savolainen MJ; Ruokonen A; Morin-Papunen L; Orešič M; Piltonen T; Tapanainen JS
    Br J Clin Pharmacol; 2015 Sep; 80(3):473-9. PubMed ID: 26095142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug-Drug Interaction Potential.
    Xue Y; Wang L; Huo R; Chen M; Melo B; Dingley K; Gaudy A; Shen JX
    Drug Metab Dispos; 2024 Aug; 52(9):966-974. PubMed ID: 38991779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?
    Yang Z; Rodrigues AD
    J Clin Pharmacol; 2010 Nov; 50(11):1330-8. PubMed ID: 20197489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.